Cabaletta Bio

Cabaletta Bio

Engineered T cell therapies designed for the treatment of patients with autoimmune diseases

Founded 2017

Philadelphia, United States 191 employees IPO Total: $322.00M Biotechnology, Pharmaceutical

Cabaletta Bio (Nasdaq: CABA) is at the forefront of innovation within the biotechnology sector, focusing on engineered T cell therapies aimed at treating autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, PA, this clinical-stage company is pioneering potentially curative medical treatments, attracting considerable attention in the biopharmaceutical field.

Leveraging their proprietary CABA™ platform, the company employs two primary strategies: CARTA and CAART. Their leading candidate, CABA-201, a CD19-CAR T therapy, is under evaluation for complex conditions like systemic lupus erythematosus. This platform, promising deep and enduring responses, positions Cabaletta Bio as a promising player in the autoimmune treatment landscape.

The company's growth trajectory is underlined by their recent Post Ipo Equity investment as of 01 June 2025, marking them as a significant opportunity for investors enthusiastic about cutting-edge therapeutic innovations.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$150.00M	4	Adage Capital Management, Cormorant Asset Management +2	01 May 2026
Post-IPO Equity	Undisclosed	-		01 Jun 2025
Post-IPO Equity	$87.00M	-		01 May 2023
Post-IPO Equity	$35.00M	3	Adage Capital Management, Cormorant Asset Management +1	01 Dec 2022
Post-IPO Equity	Undisclosed	-		01 Nov 2020
IPO	Undisclosed	-		01 Oct 2019
Series A	$50.00M	4	5AM Ventures, Boxer Capital +2	01 Jan 2019
Spinout	Undisclosed	1	University of Pennsylvania	01 Jun 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

$150.00M

Adage Capital Management, Cormorant Asset Management +2

01 May 2026

Post-IPO Equity

Undisclosed

01 Jun 2025

Post-IPO Equity

$87.00M

01 May 2023

Post-IPO Equity

$35.00M

Adage Capital Management, Cormorant Asset Management +1

01 Dec 2022

Post-IPO Equity

Undisclosed

01 Nov 2020

IPO

Undisclosed

01 Oct 2019

Series A

$50.00M

5AM Ventures, Boxer Capital +2

01 Jan 2019

Spinout

Undisclosed

University of Pennsylvania

01 Jun 2017

FAQ About Cabaletta Bio

Engineered T cell therapies designed for the treatment of patients with autoimmune diseases

Cabaletta Bio was founded in 2017.

Cabaletta Bio is headquartered in Philadelphia, United States.

Cabaletta Bio operates in Biotechnology and Pharmaceutical. Its work centres on engineered T cell therapies, autoimmune diseases, clinical-stage and CARTA strategy. Its customers include Patients with autoimmune diseases, Healthcare providers specializing in rheumatology, dermatology, and neurology and Biotechnology researchers and collaborators.

Cabaletta Bio has a B2B and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.

Cabaletta Bio has approximately 191 employees.

Cabaletta Bio has completed 8 funding rounds, raising a total of $322.00M. The latest funding stage is IPO.

Cabaletta Bio offers: Development of T cell therapies for autoimmune diseases, Conducting Phase 1/2 clinical trials, CD19 chimeric antigen receptor T cell therapy development, Research and development of CABA® platform.

Top alternatives and competitors to Cabaletta Bio include Barinthus Biotherapeutics, Immunocore, Imcyse SA, Biodexa Pharmaceuticals PLC, Autolus Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Cabaletta Bio and Barinthus Biotherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Cabaletta Bio

Services & Products

Target Customers

Funding Rounds & Investors (8)

Cabaletta Bio Alternatives & Competitors

FAQ About Cabaletta Bio